Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplant

Lucy A. Godley, Uchenna O. Njiaju, Margaret Green, Howard Weiner, Shang Lin, Olatoyosi Odenike, Elizabeth S. Rich, Andrew Artz, Koen Van Besien, Christopher K. Daugherty, Yanming Zhang, Michelle M. Le Beau, Wendy Stock, Richard A. Larson

Research output: Contribution to journalArticlepeer-review

13 Scopus citations

Abstract

Few clinical protocols have focused on patients with therapy-related myeloid neoplasms (t-MN). Therefore, we enrolled 32 patients with previously untreated t-MN on a clinical trial testing the effectiveness of a unified induction regimen of high-dose cytarabine and mitoxantrone. The complete remission (CR) rate was 66 (95 CI 4781) and the partial remission (PR) rate was 16 (95 CI 533), for an overall response rate of 82. Day 30 treatment mortality was 9 (3/32), and the most serious induction toxicity was cardiac dysfunction. Among the patients with CR, 13 (62) received consolidation therapy using an allogeneic hematopoietic cell transplant (HCT), four (21) received an autologous HCT, and three (16) received further chemotherapy. We observed long-term disease-free survival in patients who received all three types of consolidation therapy. The remission induction of high-dose cytarabine and mitoxantrone for t-MN is a well-tolerated efficacious combination, which allows aggressive consolidation and long-term disease-free survival.

Original languageEnglish (US)
Pages (from-to)995-1006
Number of pages12
JournalLeukemia and Lymphoma
Volume51
Issue number6
DOIs
StatePublished - Jun 2010

Keywords

  • High-dose cytarabine
  • Mitoxantrone
  • Therapy-related myeloid neoplasm

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplant'. Together they form a unique fingerprint.

Cite this